Chaz

This is a great financial model !  Detailed assumptions that 3 years later still seem realistic and very positive in terms of growing market cap/pps.  CRMD should be able to put together a strong value prop well north of $15/vial in HD, and In-Patient should be a lot higher than HD, making a strong story that much stronger. 

 

Another point to be considered - unlike a number of biotechs that have to continue to invest huge $s in R&D, while they build over-staffed senior mngt teams and extensive sales infrastructure, CRMD should be able to get this product on the market and start turning a profit relatively quickly with reasonable SG&A and modest R&D -

 

Also, there's high probability Oncology will be approved , more than doubling HD and In-Patient revenue.  By that point we will likely have been sold, but I hope/believ at a very big multiple of current pps.  Don't want to sound like a cheerleader as I know how long this has taken, but hopefully it will be worth it.